Molecular structure of AT7519, CAS Number: 844442-38-2
AT7519 (CAS 844442-38-2)
See product citations (1)
Alternate Names:
4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide
Application:
AT7519 is a novel small molecule effective as a pan-Cdk inhibitor for Cdk1, Cdk2, Cdk3, Cdk4, Cdk5 and Cdk6
CAS Number:
844442-38-2
Molecular Weight:
382.24
Molecular Formula:
C16H17Cl2N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AT7519 is a novel small molecule effective as a multi-cyclin-dependent kinase inhibitor for Cdk1/cyclin B (IC50 = 210 nM), Cdk2/Cyclin A (IC50 = 47 nM), Cdk3/Cyclin E (IC50 = 360 nM), Cdk4/Cyclin D1 (IC50 = 100 nM), Cdk5/p35 (IC50 = 13 nM) and Cdk6/Cyclin D3 (IC50 = 170 nM). AT7519 is an ATP competitive Cdk inhibitor with a Ki value of 38 nM for Cdk1. AT7519 is inactive against all non-Cdk kinases with the exception of GSK3β (IC50 = 89 nM). AT7519 shows potent antiproliferative activity in a variety of human tumor cell lines with IC50 values ranging from 40 nM for MCF-7 to 940 nM for SW620. AT7519 induces activation of GSK-3beta by down-regulating GSK-3beta phosphorylation, which also contributes to AT7519 induced apoptosis independent of the inhibition of transcription.
AT7519 (CAS 844442-38-2) References
- AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. | Santo, L., et al. 2010. Oncogene. 29: 2325-36. PMID: 20101221
- AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. | Squires, MS., et al. 2010. Mol Cancer Ther. 9: 920-8. PMID: 20354122
- Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. | Dolman, ME., et al. 2015. Clin Cancer Res. 21: 5100-9. PMID: 26202950
- Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer. | Xi, C., et al. 2019. Biochem Biophys Res Commun. 513: 589-593. PMID: 30979499
- Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy. | Wei, X., et al. 2020. Cancer Chemother Pharmacol. 85: 949-957. PMID: 32279103
- Inhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a p53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519. | Pourbagheri-Sigaroodi, A., et al. 2020. Iran J Pharm Res. 19: 144-155. PMID: 33680018
- Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. | Kazi, A., et al. 2021. Clin Cancer Res. 27: 4012-4024. PMID: 33879459
- Advances in targeted therapy for osteosarcoma based on molecular classification. | Chen, Y., et al. 2021. Pharmacol Res. 169: 105684. PMID: 34022396
- CDK inhibitors in cancer therapy, an overview of recent development. | Zhang, M., et al. 2021. Am J Cancer Res. 11: 1913-1935. PMID: 34094661
- The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways. | Wang, L., et al. 2022. Fundam Clin Pharmacol. 36: 81-88. PMID: 34212421
- AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss. | Hati, S., et al. 2021. Eur J Med Chem. 226: 113849. PMID: 34560429
- AT7519 against lung cancer via the IL6/STAT3 signaling pathway. | Zhou, F., et al. 2022. Biochem Biophys Res Commun. 609: 31-38. PMID: 35413537
- The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest. | Zhao, W., et al. 2023. Cell Death Dis. 14: 11. PMID: 36624090
Inhibitor of:
BC024659, Bcl-6b, C6orf126, CCDC77, Cdc6, CDD, Cdk, Cdk1, Cdk1/Cdk2, Cdk2, Cdk4, CDK5RAP, Cdk6, Cdk9, Cdx4, Clb2, Clb3, CNTD1, CPAN, cyclin δ-1, cyclin A, Cyclin A1, cyclin B, cyclin B1, cyclin C, cyclin D1, cyclin D3, cyclin E, cyclin F, cyclin G1, cyclin G2, cyclin I, cyclin T1, D-type cyclin, DMXL1, E2F-1, E2F-8, EG624855, FAM127B, FLJ32549, KBP, Ki-67, Kin28, LIN37, p130, p14 ARF/p16, p15, p27, p35, p39 (CDK5R), p57, PCID2, PCTAIRE-2, Peregrin, PITSLRE A, SERTAD4, Sic1, SPC12, Speedy A, Speedy E3, V1RG1, ZNF705A, and ZSCAN16.Activator of:
Cdc28, Cdk3, Cig2, and SOLO.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AT7519, 5 mg | sc-364416 | 5 mg | $291.00 | |||
AT7519, 10 mg | sc-364416A | 10 mg | $341.00 | |||
AT7519, 100 mg | sc-364416B | 100 mg | $1046.00 | |||
AT7519, 1 g | sc-364416C | 1 g | $3126.00 |